Jung-min Ahn
7
2
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
1 terminated/withdrawn out of 7 trials
50.0%
-36.5% vs industry average
29%
2 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
Role: lead
ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography
Role: lead
Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent
Role: lead
Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery
Role: lead
IRIS-Synergy Cohort in the IRIS-DES Registry
Role: lead
Genome-wide Association Study of Development of Collateral Circulation for Patients With Coronary or Peripheral Artery Disease
Role: lead
The Usefulness of Coronary CT Scan After Everolimus-eluting Bioabsorbable Scaffold Implantation for Coronary Artery Disease
Role: lead
All 7 trials loaded